Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is poised for success as they have achieved solid financial results, with top-line revenue and full-year earnings either meeting or exceeding projected numbers for 2025. They have a strong cash position and a positive outlook with promising clinical trials in the pipeline. Their proprietary technology and recent advancements in non-invasive depression treatment provide a competitive advantage and potential for widespread adoption. However, risks include slower-than-projected uptake, failure to expand reimbursement and market access, inability to advance in other indications, and potential long-term dilution risk.

Bears say

BrainsWay is making strategic investments in complementary businesses, while also receiving FDA approval for their at-home neuromodulation device for treatment resistant depression, which expands their potential market beyond first-generation in-clinic care. This can potentially lead to an increase in forward earnings multiple and an increase in the company's intrinsic value. However, the stock's price may also be affected by future investments and potential acquisition of Neurolief, which could add additional risk.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.